BioSpace News Archive

The growing frequency of renal diseases, alongside the noteworthy growth in geriatric population, has been a primary driver of the North America dialysis market forecast.

By 2024, the North America molecular diagnostics market share is slated to surpass USD 5.3 billion annually.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU AS IT FORMS PART OF LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN. Hemogenyx Pharmaceuticals plc (LSE:HEMO) announces that it has received a conversion notice from Mint Capital Advisors Ltd

Matrix Medical Network® (Matrix) today announced the evolution of its business into four distinct areas of focus to help address the country’s biggest health challenges

As COVID-19 activity continues in Canada, we are tracking a range of epidemiological indicators to monitor where the disease is most active, where it is spreading and how it is impacting the health of Canadians and public health, laboratory and healthcare capacity.

Aquarius Surgical Technologies Inc. (CSE:ASTI) (“ASTI” or the “Company”) announces further developments following the announcement on February 22, 2021, that Gordon Willox (“Mr. Willox”) had been removed as a director and officer of Surgical Lasers Inc. (“SLI”), the principal operating subsidiary of ASTI.

In a new study released today by the EveryLife Foundation for Rare Diseases, the estimated economic cost of 379 rare diseases in the United States totaled $966 billion in 2019, a figure that surpasses the economic burden estimated for many of the costliest chronic diseases described by the Centers for Disease Control and Prevention (CDC), including diabetes, heart disease, and cancer.

The National Marrow Donor Program® /Be The Match® announced plans to launch the ACCESS clinical trial titled A Multicenter Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Patients with Hematologic Malignancies.

Crosby will provide strategic insights and guidance on important issues from employee engagement to workplace environment

Affirms continued regulatory and industry adoption of biosimulation and technology to bring new drugs to patients